Trial Profile

A real-life prospective Brazilian multicenter phase IV study to determine safety and efficacy of COVID-19 Vaccine in patients with autoimmune inflammatory diseases

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Acronyms SAFER

15 Jun 2024 Results (n=188) assessing the safety and the influence in the disease activity of a single bivalent mRNA vaccine booster against SARS-CoV-2 in patients with RA presented at the 25th Annual Congress of the European League Against Rheumatism
15 Jun 2024 Trial design and patient characteristics presented at the 25th Annual Congress of the European League Against Rheumatism
15 Jun 2024 Results presented at the 25th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com